Complementary and Alternative Medicine Usage in Chronic Kidney Disease: Prevalence, Patterns, and Clinical Implications
Posted inNephrology Specialties

Complementary and Alternative Medicine Usage in Chronic Kidney Disease: Prevalence, Patterns, and Clinical Implications

Complementary and alternative medicine (CAM) use is prevalent in chronic kidney disease (CKD), with 43% of patients globally employing CAM modalities. Nutritional supplements, mind-body practices, and traditional medicines are widely used, yet non-disclosure to healthcare providers is common, underscoring the need for open clinical communication.
Revealing Metabolic Subtypes in Gestational Diabetes Using Dynamic OGTT-Derived C-Peptide Trajectories: Implications for Personalized Risk and Management
Posted inClinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Revealing Metabolic Subtypes in Gestational Diabetes Using Dynamic OGTT-Derived C-Peptide Trajectories: Implications for Personalized Risk and Management

Dynamic C-peptide patterns during OGTT uncover metabolic heterogeneity in GDM, identifying insulin-resistant women at risk for fetal overgrowth and normoglycemic women at risk for preeclampsia, suggesting improved stratified treatment beyond glucose-based diagnosis.
Unveiling the Impact of Pre-Clinical Alzheimer’s Disease on Blood Pressure: Insights from UK Biobank Mendelian Randomisation Studies
Posted inCardiology Neurology Specialties

Unveiling the Impact of Pre-Clinical Alzheimer’s Disease on Blood Pressure: Insights from UK Biobank Mendelian Randomisation Studies

This study presents compelling evidence that pre-clinical Alzheimer’s disease increases systolic blood pressure, using innovative Mendelian randomisation and parental dementia instruments in UK Biobank data. These findings highlight complex vascular interactions preceding clinical dementia.
Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up
Posted inHematology-Oncology Specialties

Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up

Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell lymphoma with a favorable safety profile.